Navigation Links
New lab mice cut search for genetic links to disease by more than a decade

With a 95 percent genomic similarity to humans, mice have long been used to learn about the genetic causes of human disease. Once researchers can shine a light on the genetic factors that cause disease in mice, they can start to develop prevention and treatment options to protect the human population.

But this process, called genetic mapping, is a long and difficult road, made more challenging by the 5% difference between the humans and lab mice. Now Prof. Fuad Iraqi of Tel Aviv University's Sackler Faculty of Medicine is closing the gap with an international project called Collaborative Cross. The project is developing lab mice with increased genetic diversity, making them more advantageous for genetic research related to human health.

The new population will offer 1,000 genetic strains within a fixed genotype the composite of the entire genetic makeup of an organism. This is a marked improvement on the previously existing 450 genetic strains of lab mice with varying genotypes, making Prof. Iraqi's new strain ideal for genetic mapping. And with these mice, researchers will be able to identify a gene associated with a particular disease within two to three years instead of the 10 to 15 years it takes now, says Prof. Iraqi.

The research has been published in the journals Nature, Nature Genetics, and Genome Research, and receives its primary funding from the Wellcome Trust in the UK. The project itself is a collaboration among Tel Aviv University, Oxford University in the UK, North Carolina State University in the US, and Perth University in Australia.

Expanding the family tree

Genetic determinants play an important role in a variety of conditions from diabetes and obesity to different types of cancers. For example, mutated forms of the genes BRCA1 and BRCA2, which can be genetically inherited, are associated with higher rates of breast and ovarian cancers. This kind of genetic diversity in humans influences diseases and helps researchers track their genetic causes. According to Prof. Iraqi, the fact that humans have many genetic variances for the same gene means that they are "outbred" among individuals from different families. To best identify the genes that cause a disease, scientists require a test population with these same variances.

But standard strains of lab mice are inbred. Their genetic similarities make it difficult to identify the connection between particular traits and the specific genes responsible. The Collaborative Cross project answers this deficiency in lab mice by increasing genetic variation as much as possible a powerful and unique resource for research.

In order to develop a genetically enriched population of lab mice, the researchers took five classic inbred strains of mice and mixed them with three wild-derived strains, mating brothers and sisters for generations in order to reshuffle the genetic deck but keep the genotype consistent. With an increased range of traits, including differences in appearance such as fur color and tail length, this new mouse population more closely mimics the genetic diversity of humans, says Prof. Iraqi.

Building a better mouse

The various genetic strains are housed within participating universities across the world, notes Prof. Iraqi, and are already available for order by researchers. Within Tel Aviv University's laboratories, there are currently genetic mapping projects for a variety of diseases, including diabetes, various types of cancers, dental infections, bacterial infections, and fungal infections all making use of these genetically enriched mice.

Prof. Iraqi has already used the new mouse population to identify a group of genes that are crucial to susceptibility to infection when exposed to Aspergillus fumigatus, a soil fungus that causes respiratory infections in humans. Getting to this point took only a year compared to the 15 years it might have taken using standard lab mice, he calculates.


Contact: George Hunka
American Friends of Tel Aviv University

Related biology news :

1. Minneapolis Heart Institute selected to participate in Cardiovascular Cell Therapy Research Network
2. Improving equine health: Research studies vaccinations to protect newborn foals
3. Stomata development in plants unraveled -- a valuable discovery for environmental research
4. Incisive research links teeth with diet
5. SFU HIV/AIDS vaccine research gets financial boost
6. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
7. Plant research reveals new role for gene silencing protein
8. Tales from the crypt lead researchers to cancer discovery
9. LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men
10. Researcher who identifed genetic cause and possible treatment for Marfan syndrome honored
11. EU project: Searching for exotics in the shrimp nets
Post Your Comments:
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
(Date:6/23/2016)... 23, 2016 adds ... to its pharmaceuticals section with historic and forecast ... much more. Complete report on the ... profiling 15 companies and supported with 261 tables ... . The Global Cell Culture ...
Breaking Biology Technology: